PLUS THERAPEUTICS FILES 8-K WITH MATERIAL AGREEMENT

TL;DR

PLUS THERAPEUTICS (PSTX) filed an 8-K on 5/5/24 for a material agreement - could be equity sale.

AI Summary

On May 5, 2024, PLUS THERAPEUTICS, INC. entered into a material definitive agreement, potentially related to unregistered sales of equity securities. The filing also includes financial statements and exhibits. The company was formerly known as CYTORI THERAPEUTICS, INC. and MACROPORE INC.

Why It Matters

This 8-K filing indicates a significant event for PLUS THERAPEUTICS, INC., potentially involving new financing or strategic partnerships that could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — Material definitive agreements and unregistered sales of equity can introduce financial risks and dilution for existing shareholders.

Key Players & Entities

• PLUS THERAPEUTICS, INC. (company) — Registrant
• CYTORI THERAPEUTICS, INC. (company) — Former Company Name
• MACROPORE INC (company) — Former Company Name
• May 5, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share PSTV The Nasdaq
• $6.5 million — ate (as defined below) of approximately $6.5 million. On May 8, 2024, the Company entered in
• $0.75 million — te subscription amount by approximately $0.75 million (the "Additional Subscription") for agg
• $7.25 million — initial gross proceeds of approximately $7.25 million. The Securities Purchase Agreement, as
• $2.022 — ties." The combined purchase price of $2.022 for each Private Placement Share and Pr
• $2.158 — rrant from the Initial Subscription and $2.158 from the Additional Subscription, in ea
• $2.04 — al Subscription at an offering price of $2.04 per Private Placement Share and accompa
• $1.772 — arrant from the Initial Subscription is $1.772 per share and $1.908 per share in the A
• $1.908 — al Subscription is $1.772 per share and $1.908 per share in the Additional Subscriptio
• $1.79 — rants issued to the Company Insiders is $1.79 per share. The participation of the Com
• $98,500 — e Board. The Company Insiders purchased $98,500 of Securities in the aggregate. The c
• $7.25 m — ate are expected to total approximately $7.25 million, before deducting certain expense
• $12.0 million — e gross proceeds of up to approximately $12.0 million for an aggregate of up to approximately
• $19.25 million — for an aggregate of up to approximately $19.25 million in gross proceeds. The Series A Warra

Filing Documents

• d827838d8k.htm (8-K) — 39KB
• d827838dex41.htm (EX-4.1) — 78KB
• d827838dex42.htm (EX-4.2) — 95KB
• d827838dex43.htm (EX-4.3) — 93KB
• d827838dex101.htm (EX-10.1) — 246KB
• d827838dex102.htm (EX-10.2) — 20KB
• d827838dex103.htm (EX-10.3) — 121KB
• 0001193125-24-135399.txt ( ) — 981KB
• pstv-20240505.xsd (EX-101.SCH) — 3KB
• pstv-20240505_lab.xml (EX-101.LAB) — 18KB
• pstv-20240505_pre.xml (EX-101.PRE) — 11KB
• d827838d8k_htm.xml (XML) — 4KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Number Description 4.1 Form of Pre-Funded Warrant 4.2 Form of Series A Warrant 4.3 Form of Series B Warrant 10.1* Securities Purchase Agreement, dated as of May 5, 2024, by and among Plus Therapeutics, Inc. and the purchasers named therein 10.2 First Amendment to Securities Purchase Agreement, dated as of May 8, 2024, by and among Plus Therapeutics, Inc. and the purchasers named therein 10.3 Registration Rights Agreement, dated as of May 5, 2024, by and among Plus Therapeutics, Inc. and the purchasers named therein 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Schedules and exhibits have been omitted from this exhibit pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the SEC.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLUS THERAPEUTICS, INC. Date: May 9, 2024 By: /s/ Andrew Sims Name: Andrew Sims Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR